新天药业(002873) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was ¥34,567,925.02, reflecting a year-on-year growth of 7.60%[8] - Operating revenue for the period was ¥224,431,070.25, representing an increase of 11.22% compared to the same period last year[8] - The net profit after deducting non-recurring gains and losses was ¥34,696,708.04, up 9.63% year-on-year[8] - The company reported a total profit of ¥45,018,977.14, compared to ¥37,106,021.58 in the previous period, which is an increase of approximately 21.5%[38] - The net profit for the current period was ¥34,203,866.45, up from ¥31,962,830.77, which is an increase of around 7.8%[39] - The net profit for the period was ¥69,085,362.97, representing a 6.43% increase from ¥64,845,284.57 in the same period last year[46] Earnings and Shareholder Information - Basic earnings per share decreased by 5.88% to ¥0.2992[8] - Basic and diluted earnings per share for the current period were both ¥0.2992, down from ¥0.3179 in the previous period, reflecting a decrease of about 5.5%[39] - Basic and diluted earnings per share were both ¥0.6020, down from ¥0.8168 in the previous period[47] - The total number of shareholders at the end of the reporting period was 13,564[12] - The largest shareholder, Guiyang Xintian Biotechnology Development Co., Ltd., held 44.04% of the shares[12] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,126,444,464.17, an increase of 14.44% compared to the previous year[8] - Current assets rose to CNY 705,332,081.48, compared to CNY 628,299,976.31, reflecting an increase of about 12.3%[28] - Non-current assets totaled CNY 421,112,382.69, up from CNY 356,013,123.20, marking a growth of approximately 18.3%[28] - Current liabilities increased to CNY 366,238,071.04 from CNY 296,763,762.35, which is an increase of around 23.3%[29] - Total liabilities reached CNY 412,069,890.93, compared to CNY 323,724,363.99, indicating a rise of approximately 27.4%[29] - Owner's equity rose to CNY 714,374,573.24 from CNY 660,588,735.52, reflecting an increase of about 8.1%[30] Cash Flow and Investments - The net cash flow from operating activities decreased significantly by 95.04% to ¥1,821,421.82[8] - Cash and cash equivalents increased by 83.56% to ¥255.61 million, primarily due to the redemption of financial products[17] - Cash flow from investing activities showed a net inflow of ¥25.19 million, a turnaround from a net outflow of ¥58.74 million in the previous period[17] - The total cash flow from operating activities was ¥584,514,487.57, compared to ¥519,555,684.35 in the previous period[53] - The company received CNY 280,000,000.00 from investment recoveries, down from CNY 513,000,000.00 in the previous year[58] Expenses - Total operating costs amounted to ¥177,452,084.68, up from ¥164,922,189.08, reflecting a growth of about 7.4%[37] - Research and development expenses decreased to ¥8,370,809.73 from ¥9,360,309.12, a reduction of approximately 10.6%[37] - Sales expenses increased to ¥92,136,035.99 from ¥88,846,250.90, marking an increase of about 2.9%[37] - The income tax expense for the current period was ¥10,815,110.69, significantly higher than ¥5,143,190.81 in the previous period, indicating an increase of about 109.5%[38] - The company recorded an asset impairment loss of ¥1,997,872.34, compared to ¥1,207,867.59 in the previous period, reflecting an increase of approximately 65.3%[39] Share Buyback - The company repurchased 1,582,500 shares for a total of ¥25.50 million during the buyback period[19] - The company plans to continue repurchasing shares with a budget of between ¥10 million and ¥20 million, at a price not exceeding ¥20 per share[19]